论文部分内容阅读
目的观察吉西他滨联合顺铂治疗复发或转移性鼻咽癌的临床疗效和不良反应。方法吉西他滨1 000 mg/m2,分别于第1天和第8天静脉点滴;顺铂80 mg/m2,第1天,或顺铂每天20 mg/m2,第1~4天,21天为1个周期,所有病例接受至少2个周期的化疗。结果28例患者入组,完全缓解6例,部分缓解18例,总有效率为85.7%(24/28)。中位随访时间15个月(6~23个月),1年生存率为86%,中位疾病进展时间为8.6个月(2.5~18个月)。主要不良反应为骨髓抑制及恶心、呕吐,有4例(14%,4/28)发生了Ⅲ~Ⅳ度骨髓毒性。结论吉西他滨联合顺铂方案治疗复发或转移性鼻咽癌有较好的疗效,患者耐受性好,值得临床进一步研究。
Objective To observe the clinical efficacy and side effects of gemcitabine combined with cisplatin in the treatment of recurrent or metastatic nasopharyngeal carcinoma. Methods Gemcitabine 1 000 mg / m2 intravenously on days 1 and 8 respectively; cisplatin 80 mg / m2 on day 1 or cisplatin 20 mg / m2 on day 1 to day 1 and 21 on day 1 A cycle, all cases received at least 2 cycles of chemotherapy. Results Twenty - eight patients were enrolled in this study. Six patients were completely relieved and 18 patients partially relieved. The total effective rate was 85.7% (24/28). The median follow-up time was 15 months (range, 6-23 months), 1-year survival was 86%, and median disease progression was 8.6 months (2.5-18 months). The main adverse reactions were myelosuppression and nausea and vomiting. There were 4 (14%, 4/28) cases of grade Ⅲ ~ Ⅳ myelotoxicity. Conclusion Gemcitabine combined with cisplatin in the treatment of recurrent or metastatic nasopharyngeal carcinoma has a good effect, patients with good tolerance, it is worth further clinical study.